| European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013 M Baccarani, MW Deininger, G Rosti, A Hochhaus, S Soverini, ... Blood, The Journal of the American Society of Hematology 122 (6), 872-884, 2013 | 2552 | 2013 |
| Dasatinib in imatinib-resistant Philadelphia chromosome–positive leukemias M Talpaz, NP Shah, H Kantarjian, N Donato, J Nicoll, R Paquette, ... New England Journal of Medicine 354 (24), 2531-2541, 2006 | 2164 | 2006 |
| A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome J Cools, DJ DeAngelo, J Gotlib, EH Stover, RD Legare, J Cortes, J Kutok, ... New England Journal of Medicine 348 (13), 1201-1214, 2003 | 2147 | 2003 |
| Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia H Kantarjian, NP Shah, A Hochhaus, J Cortes, S Shah, M Ayala, ... New England Journal of Medicine 362 (24), 2260-2270, 2010 | 1960 | 2010 |
| Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet M Baccarani, J Cortes, F Pane, D Niederwieser, G Saglio, J Apperley, ... Journal of clinical oncology 27 (35), 6041, 2009 | 1855 | 2009 |
| Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet M Baccarani, G Saglio, J Goldman, A Hochhaus, B Simonsson, ... Blood 108 (6), 1809-1820, 2006 | 1825 | 2006 |
| Nilotinib in imatinib-resistant CML and Philadelphia chromosome–positive ALL H Kantarjian, F Giles, L Wunderle, K Bhalla, S O'Brien, B Wassmann, ... New England Journal of Medicine 354 (24), 2542-2551, 2006 | 1633 | 2006 |
| Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL … T Hughes, M Deininger, A Hochhaus, S Branford, J Radich, J Kaeda, ... Blood 108 (1), 28-37, 2006 | 1527 | 2006 |
| Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia MJ Keating, S O’Brien, M Albitar, S Lerner, W Plunkett, F Giles, M Andreeff, ... Journal of clinical oncology 23 (18), 4079-4088, 2005 | 1315 | 2005 |
| A phase 2 trial of ponatinib in Philadelphia chromosome–positive leukemias JE Cortes, DW Kim, J Pinilla-Ibarz, P Le Coutre, R Paquette, C Chuah, ... New England Journal of Medicine 369 (19), 1783-1796, 2013 | 1228 | 2013 |
| Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2′-deoxycytidine (decitabine) in hematopoietic malignancies JPJ Issa, G Garcia-Manero, FJ Giles, R Mannari, D Thomas, S Faderl, ... Blood 103 (5), 1635-1640, 2004 | 1025 | 2004 |
| Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia H Kantarjian, Y Oki, G Garcia-Manero, X Huang, S O'Brien, J Cortes, ... Blood 109 (1), 52-57, 2007 | 958 | 2007 |
| Final 5-year study results of DASISION: the dasatinib versus imatinib study in treatment-naïve chronic myeloid leukemia patients trial JE Cortes, G Saglio, HM Kantarjian, M Baccarani, J Mayer, C Boqué, ... Journal of Clinical Oncology 34 (20), 2333, 2016 | 955 | 2016 |
| Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia HM Kantarjian, S O’Brien, TL Smith, J Cortes, FJ Giles, M Beran, S Pierce, ... Journal of Clinical Oncology 18 (3), 547-547, 2000 | 942 | 2000 |
| Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity AS Corbin, A Agarwal, M Loriaux, J Cortes, MW Deininger, BJ Druker The Journal of clinical investigation 121 (1), 396-409, 2011 | 935 | 2011 |
| Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia CS Tam, S O'Brien, W Wierda, H Kantarjian, S Wen, KA Do, DA Thomas, ... Blood, The Journal of the American Society of Hematology 112 (4), 975-980, 2008 | 913 | 2008 |
| Molecular biology of bcr-abl1–positive chronic myeloid leukemia A Quintás-Cardama, J Cortes Blood, The Journal of the American Society of Hematology 113 (8), 1619-1630, 2009 | 899 | 2009 |
| Ponatinib in refractory Philadelphia chromosome–positive leukemias JE Cortes, H Kantarjian, NP Shah, D Bixby, MJ Mauro, I Flinn, T O'Hare, ... New England Journal of Medicine 367 (22), 2075-2088, 2012 | 895 | 2012 |
| Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION) HM Kantarjian, NP Shah, JE Cortes, M Baccarani, MB Agarwal, ... Blood, The Journal of the American Society of Hematology 119 (5), 1123-1129, 2012 | 786 | 2012 |
| Rituximab dose-escalation trial in chronic lymphocytic leukemia SM O’Brien, H Kantarjian, DA Thomas, FJ Giles, EJ Freireich, J Cortes, ... Journal of Clinical Oncology 19 (8), 2165-2170, 2001 | 777 | 2001 |
Guillermo Garcia-ManeroMD Anderson Cancer CenterVerified email at mdanderson.org
